Throughout one’s life, cells divide until they encounter some form of biologic stress, at which point they pull a form of cellular emergency brake causing them to cease dividing forever.
The result is an accumulation of senescent cells that secrete large quantities of harmful proteins, which cause inflammation, tissue degradation, and the production of growth factors that alter the tissue microenvironment, which is believed to lead to age-associated diseases.
This is where senolytics come into play,by eliminating accumulated senescent cells that facilitate aging and drive many of the common age-associated diseases we deal with today. Some of these include cardiovascular disease, Type 2 diabetes, hypertension, hearing loss, and osteoporosis.
This is huge! How huge?
Well, according to the Longevity Fund, a venture capital firm that invests specifically in anti-aging related companies, a single age-related indication could be worth a couple hundred billion dollars.
That’s roughly the GDP of Portugal. From a single age-related indication!
My friends, don’t think for a second that I’m not getting a piece of this action. And you should, too.
But which anti-aging company is best in the breed?
READ MORE: Energy & Capital
Laura Deming is the founder and full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the ageing process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.[ sponsored ]